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Abstract
Background: Alzheimer disease (AD) is the most common form of dementia but the identification of reliable, early
and non-invasive biomarkers remains a major challenge. We present a novel miRNA-based signature for detecting
AD from blood samples.
Results: We apply next-generation sequencing to miRNAs from blood samples of 48 AD patients and 22
unaffected controls, yielding a total of 140 unique mature miRNAs with significantly changed expression levels.
Of these, 82 have higher and 58 have lower abundance in AD patient samples. We selected a panel of 12 miRNAs
for an RT-qPCR analysis on a larger cohort of 202 samples, comprising not only AD patients and healthy controls
but also patients with other CNS illnesses. These included mild cognitive impairment, which is assumed to
represent a transitional period before the development of AD, as well as multiple sclerosis, Parkinson disease, major
depression, bipolar disorder and schizophrenia. miRNA target enrichment analysis of the selected 12 miRNAs
indicates an involvement of miRNAs in nervous system development, neuron projection, neuron projection
development and neuron projection morphogenesis. Using this 12-miRNA signature, we differentiate between AD
and controls with an accuracy of 93%, a specificity of 95% and a sensitivity of 92%. The differentiation of AD from
other neurological diseases is possible with accuracies between 74% and 78%. The differentiation of the other CNS
disorders from controls yields even higher accuracies.
Conclusions: The data indicate that deregulated miRNAs in blood might be used as biomarkers in the diagnosis of
AD or other neurological diseases.
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Background
Alzheimer disease(AD) is the most common form of
neurodegenerative illness leading to dementia which is
predicted to affect as much as 1 in 85 people globally by
2050 [1]. While early-onset (familiar) AD has been
reported in younger people, the majority of (sporadic)
AD cases is diagnosed in people aged over 65 years [2].
As of today, final diagnosis of AD can only be achieved
by autopsy making the identification of reliable, early, and
non-invasive biomarkers a major challenge. Finding such
non-invasive, reliable diagnostic tools is of paramount
importance as it appears that early intervention in the pro-
dromal stage of AD or the identification and therapy of
those patients with mild cognitive impairment who will
transform to AD rapidly might be a possibility to delay the
onset of AD substantially [3].
A prominent example of recently developed AD bio-
marker assays is the combinatorial analysis of the con-
centration of peptides and proteins: beta-amyloid-1-42
(Aß 42), tau, and/or p-tau in the cerebrospinal fluid
(CSF). According to the S3 guidelines, an increased level
of tau protein together with a decreased level of beta-
amyloid-1-42 provides strong evidence for the presence
of AD [4]. The combinatorial analysis of all three factors
yields even higher diagnostic accuracy than the combi-
nation of only two of the above-mentioned proteins [5].
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Furthermore, combinatorial analysis of Aß levels and tau
levels can discriminate between patients with stable mild
cognitive impairment (MCI) and patients with progres-
sive MCI into AD or other types of dementia with a suf-
ficient diagnostic accuracy [6]. Nevertheless, according
to the S3 guidelines, the analysis of CSF biomarker is
only indicated to confirm the diagnosis if other clinical
symptoms give evidence for the presence of neurode-
generative dementia or for the differential diagnostics of
other forms of diseases that can cause symptoms like
dementia (encephalitis, neuroborreliosis, multiple sclero-
sis, Lues, brain abscess, metastases).
The use of peripheral markers, like Aß and tau in
easily accessible peripheral cells (in particular platelets
and skin fibroblasts), as a diagnostic tool has been
under investigation for more than 10 years [7,8]. Mole-
cular genetics analyses of common single nucleotide
polymorphisms (SNPs) in genes such as presenilin or
ApoE4 did not significantly improve risk estimation for
the susceptibility of AD [9]. Likewise, there is no consis-
tent evidence for an association between AD and genetic
variation of mitochondrial DNA (mtDNA) [10].
There is increasing effort to develop molecular diagnos-
tic markers that meet requirements like easy accessibility,
for example, from blood, sufficiently high specificity and
sensitivity, low costs and applicability by laboratories with
standard equipment. Several blood, plasma, or serum born
AD biomarkers have been proposed to meet these criteria.
Doecke et al. recently presented a panel of protein biomar-
kers to reliably detect AD with an accuracy of 85% [11].
Moreover, Tan et al. provided evidence that the proteins
p53 and p21 can be used to detect AD using blood sam-
ples. A receiver operating characteristic curve analysis
revealed a specificity of 76% and a sensitivity of 84% for
p53, 88% and 82% for p53(ser15), 80% and 75% for p21,
and 84% and 68% for p21(thr145) [12].
Besides proteins microRNAs (miRNAs) have also
demonstrated their potential as non-invasive biomarkers
from blood and serum for a wide variety of human
pathologies [13]. A deregulation of miRNA expression
might be involved in neurological dysfunction or neuro-
degenerative processes. Interestingly, Liang et al. [14]
showed that the expression pattern of brain and blood
PBMC cluster together which might be an indication that
a specific blood based expression signature might prove
to be useful as biomarker for AD and other neurological
diseases. MiRNA expression analyses can be readily
applied for in vitro diagnostic testing by molecular diag-
nostics and CLIA (Clinical Laboratory Improvement
Amendments) laboratories.
While altered miRNA patterns have been exhaustively
investigated in AD patients’ tissue samples or cell cultures
[15-18], less information on circulating miRNAs in AD is
known. A recent serum profiling of AD patients provided
first evidence that expression changes of circulating miR-
NAs may be valuable biomarkers for AD [19].
We describe our results obtained by applying the next-
generation sequencing (NGS) approach to screen the
expression of all human miRNAs in blood from exten-
sively characterized AD patients and healthy controls.
Patient blood was obtained from the SAMPLE (Serial
Alzheimer diseaseand MCI Prospective Longitudinal Eva-
luation) Registry of PrecisionMed (San Diego, CA, USA)
and blood from age-matched healthy donors from the
ACE (Aging Cognition Evaluation) Registry, a Preci-
sionMed- UBC (The University of British Columbia) col-
laboration. We identified 140 unique differentially
expressed miRNAs between AD patients and controls.
Validation of a 12-miRNA signature was carried out by
RT-qPCR in a cohort of 202 samples encompassing
patients suffering from other neurological disorders
including mild cognitive impairment as a potential preli-
minary stage of AD, and other neurodegenerative dis-
eases like Parkinson disease and multiple sclerosis as well
as mental diseases like schizophrenia (SCHIZ), major
depression (DEP), and bipolar disorder (BD).
A combination of AD-specific miRNA expression signa-
tures with the rapidly developing and expanding amyloid
load imaging techniques may be useful as non-invasive
diagnostic tools in AD diagnosis in the future [20].
Results
Initial biomarker screening using next-generation
sequencing
To detect potential AD biomarkers we examined blood
from well-characterized patients and controls. We
obtained blood from the SAMPLE (Serial Alzheimer disea-
seand MCI Prospective Longitudinal Evaluation) Registry
of PrecisionMed (San Diego, CA, USA). SAMPLE is a
sample depository resulting from a longitudinal study that
evaluates cognition in women and men, who are recruited,
evaluated, cognitively studied, and sampled from 12 to 15
experienced investigative sites in USA. All participants
underwent several tests (that is, Alzheimer Disease Assess-
ment Scale-cognitive subscale (ADAS-Cog), Clinical
Dementia Rating (CDR), Wechsler Memory Scale, and
Mini-Mental State Exam (MMSE)) to evaluate cognition.
Blood from age-matched healthy donors was obtained
from the Ace Registry, which is a biological sample bank
of serial patient samples with linked serial cognition data,
based on a cognition battery selected from UBC’s proprie-
tary computerized testing platform.
We carried out high-throughput NGS of 22 healthy
control samples (C) and 48 AD patient samples using Illu-
minaHiSeq 2000 sequencing with eight multiplexed sam-
ples on each sequencing lane. We detected not only
known human miRNAs, but also novel miRNA candidates
that have previously not been included in the miRBase
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v18 [21,22]. These miRNA candidates are, however, much
less abundant compared to the known human miRNAs.
After removing the least abundant miRNAs (that is, all
miRNAs with <50 read counts summed up across all sam-
ples of each group) we detected a total of 383 different
miRNA precursors resulting in 416 unique mature
miRNA forms.
To compare the NGS results of the AD patient sam-
ples with the samples from healthy donors we first com-
puted Wilcoxon-Mann-Whitney (WMW) test and
adjusted the significance values for multiple testing
using Benjamini-Hochberg adjustment. All miRNAs
with adjusted significance values <0.05 were considered
statistically significant. We also computed the area
under the receiver operator characteristics curve (AUC).
In total, we detected 180 significantly dys-regulated
miRNAs (140 unique mature miRNAs) including 90
miRNAs (58 unique mature miRNAs) that were down-
regulated and 90 miRNAs (82 unique mature miRNAs)
that were upregulated in AD samples compared to
healthy control samples (see Additional file 1-Table S1).
Additional file 2-Figure S1 shows a heatmap for 180 sig-
nificantly dys-regulated miRNAs. The most upregulated
miRNA was hsa-miR-30d-5p (AUC of 0.0819) with a P
value of 8.35*10-6and the most downregulated miRNA
was hsa-miR-144-5p (AUC of 0.9138) with P value of
8.35*10-6. While the high AUC value indicates that each
of these miRNAs has sufficient power to differentiate
between AD and healthy controls, they are not specific
for AD since both miRNAs have already been described
for many other human pathologies, including different
neoplasms [13]. Among the significantly dys-regulated
miRNAs are also 15 novel miRNA candidates (called
brain-miR) that were all upregulated in AD compared to
controls. A list of all novel mature miRNAs is provided
in Additional file 3-Table S2. To gain first insight into
the biological function of the mature miRNAs that were
dys-regulated between AD patients and healthy control
individuals, we applied a miRNA over-representation
analysis for these miRNAs using the TAM (tool for
annotations of human miRNAs) database [23,24]. The
TAM database classifies over- or under-represented
miRNAs according to the categories miRNA family,
miRNA cluster, miRNA function, miRNA associated
diseases, and tissue specificity. We detected for all
dys-regulated miRNAs 56 significant categories (P value
<0.05 after adjustment for multiple testing), with the
interesting categories miR-30 family with five miRNAs
being upregulated (P value 6.64*10-4), the let-7 family
with nine downregulated miRNAs (P value 5.65*10-7),
and the disease category Alzheimer disease for which six
dys-regulated miRNAs were relevant, including hsa-miR-
21, hsa-miR-17, hsa-miR-29a, hsa-miR-29b, hsa-miR-106b,
and hsa-miR-107 (P value 0.0139).
To determine whether the 140 unique differentially
expressed miRNAs between AD patients and healthy
controls cluster together within a same genomic region,
which would suggest presence of common regulatory
mechanisms for their expression, we sorted all miRNAs
according to their position on each chromosome. Then,
we assigned the miRNAs to one of the following three
classes: not dys-regulated; upregulated in AD; and
downregulated in AD. Finally, we searched for regions
that contain at least three different dys-regulated mature
miRNAs by applying window sizes varying between
1,000 and 100,000 base pairs. Within regions encom-
passing <1,000 base pairs we detected two clusters
including one on chromosome 19 with the upregulated
miRNAs hsa-miR-99b-5p and hsa-miR-125a-5p and the
downregulated miRNA hsa-let-7e-5p and a second clus-
ter on chromosome 22 with the downregulated miRNAs
hsa-let-7a-5p and hsa-let-7b-5p and the upregulated
miRNA hsa-let-7b-3p. Analyzing regions of up to 5,000
base pairs, we found on chromosome 9 a dense cluster
with a total of five dys-regulated miRNAs including the
downregulated miRNAs hsa-let-7a-5p, hsa-let-7f-5p, and
hsa-let-7d-5p and the upregulated miRNAs hsa-let-7f-1-
3p and hsa-let-7d-3p. For regions up to 30,000 base
pairs, we discovered one region on chromosome 6 with
three co-located miRNAs including hsa-miR-30c-5p,
hsa-miR-30a-3p, and hsa-miR-30a-5p, all of which were
upregulated. To understand whether the miRNAs are
regulated by specific transcription factors (TF), we
extracted potential TF binding sites from the UCSC gen-
ome browser but found no evidence for a significant
enrichment for specific TF binding sites.
In the next step, we performed classification of AD and
control samples using a standard machine learning
approach. In a cross-validation loop, we stepwise added
the miRNAs with lowest significance values and repeat-
edly carried out radial basis function support vector
machines (SVM). As shown in Figure 1, a signature of
250 miRNAs yields an accuracy, specificity, and sensitiv-
ity of 90%. Since this set of miRNAs contains a significant
amount of redundant miRNAs with largely identical
information and high correlation among many miRNAs,
a significantly smaller set of miRNAs is likely to yield
comparably accurate distinction between AD samples
and samples from healthy controls. We selected 12 miR-
NAs with limited cross-correlation, including strongly
dys-regulated miRNAs that show a potential to separate
AD from controls. We furthermore compared our NGS
results with previous studies on different types of cancer
and non-cancer diseases [13] in order to ensure that the
selected miRNAs are not dys-regulated in several other
diseases. Besides known miRNAs we also included two
unknown miRNAs, namely brain-miR-112 and brain-
miR-161. Finally, the selected 12-miRNA signature
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contains the miRNAs brain-miR-112, brain-miR-161,
hsa-let-7d-3p, hsa-miR-5010-3p, hsa-miR-26a-5p, hsa-
miR-1285-5p, and hsa-miR-151a-3p, all of which are
upregulated in AD and the downregulated miRNAs hsa-
miR-103a-3p, hsa-miR-107, hsa-miR-532-5p, hsa-miR-
26b-5p, and hsa-let-7f-5p.
Validation of a 12-miRNA signature by RT-qPCR
To validate the 12-miRNA signature we employed RT-
qPCR and included not only additional patients with
AD, but also patients with other diseases including neu-
rological disorders. In total, we analyzed 12 miRNAs in
202 samples as detailed in Table 1.
We first considered the miRNA fold quotients that
were obtained for AD samples and controls. We com-
pared the fold quotients of each of the 12 miRNAs
between initial NGS screening cohort and the RT-qPCR
validation cohort. All but two of the 12 miRNAs, namely
hsa-miR-1285-5p and hsa-miR-26a-5p, have been dys-
regulated in the same direction in both approaches, indi-
cating a high degree of concordance between screening
and validation study. Both hsa-miR-1285-5p and hsa-
miR-26a-5p have been significantly upregulated in AD in
the NGS screening experiment while downregulated in
the RT-qPCR validation (see Figure 2). This discrepancy
might be due to the duplication of the AD sample cohort.
However, SVM classification on the RT-qPCR data to
separate AD and controls using linear kernels in 10-fold
cross-validations with 100 repetitions reached on average
an accuracy of 93.3%, a specificity of 95.1%, and a sensi-
tivity of 91.5%. The computed means, standard devia-
tions, and confidence intervals for the repetitions
concerning specificity, sensitivity, and accuracy are pre-
sented in Table 2, as well as the results for the control
classifications with the randomly permuted class labels.
To evaluate whether the selected miRNAs are stage-
dependent we further grouped the AD patients accord-
ing to their MMSE score into mild AD (MMSE >19,
n = 39) and moderate AD (MMSE 12-19, n = 46). The
MMSE is a short test of 30 questions used to screen for
cognitive impairment. Each question to be answered is
scored with points, with a maximum possible score of
30 points. This questionnaire can be used to estimate
the severity of cognitive impairment and to follow the
course of cognitive changes in an individual over time.
Normally, patients reaching 27 to 30 points do not suf-
fer from dementia, 10 to 26 points are indicative for
mild-to-moderate dementia, and less than 9 points indi-
cates severe dementia. We found no significant expres-
sion differences of the 12-miRNA signature between the
mild AD group and the moderate AD group.
As patients with other neurological disorders can show
similar symptoms as AD patients, we decided to validate
our AD NGS results also with samples from patients
with several neurological diseases. Specifically, we asked
whether other neurological disorders show significant
deviations in the expression of the 12 miRNAs. The
results of this validation help to determine whether the
investigated miRNAs have the potential for clinical appli-
cations. We analyzed patients with neurodegenerative
diseases (MCI, Parkinson disease (PD), multiple sclerosis
(clinically isolated syndrome, CIS)) and patients with psy-
chiatric disorders (SCHIZ, BD, and DEP) for the signa-
ture of 12 miRNAs. The pattern, which was closest to
Figure 1 Classification performance dependent on miRNA
combinations. With increasing number of miRNAs the accuracy,
specificity, and sensitivity increases towards convergence at 90%.
Table 1 Overview of the blood samples analyzed using NGS and RT-qPCR
Sample group N Age (mean ± SD) Sex (female/male) MMSE (mean ± SD) Cohort size
NGS
Cohort size
RT-qPCR
AD 106 72.7(10.4) 53/53 18.9 (3.4) 48 94
Healthy control 22 67.1 (7.5) 11/11 29.3 (1.2) 22 21
Mild cognitive impairment 18 73.9 (6.2) 9/9 25.3 (1.4) - 18
Multiple sclerosis 16 32.3 (10.7) 12/4 NA - 16
PD 9 69.7 (9.0) 1/8 25.2 (4.2) - 9
DEP 15 45.2 (9.1) 0/15 NA - 15
BD 15 41.9 (13.7) 14/1 29.5 (1.6) - 15
SCHIZ 14 41.7 (7.9) 1/13 26.1 (4.3) - 14
AD: Alzheimer disease; BD: bipolar disorder; DEP: major depression; MMSE: Mini-Mental State Exam; NA: not available; NGS: next-generation sequencing; PD:
Parkinson’s disease; RT-qPCR: quantitative real-time PCR; SCHIZ: schizophrenia.
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Figure 2 Comparison of the expression analysis results of AD patients versus healthy controls (fold changes) obtained by NGS and RT-
qPCR for the 12-miRNA signature.
Table 2 Summary of the SVM classifications containing the means, standard deviations, and 95% confidence intervals
(CI) of the accuracy (acc), specificity (spec), sensitivity (sens) running 100 repetitions of 10-fold cross-validations with
linear kernel.
Comparison Classification Permutation test
Acc Spec Sens Acc Spec Sens
AD vs. control 93.3% ± 4.6
CI:92.4-94.2%
95.1% ± 5.4
CI:94.1-96.2%
91.5% ± 5.8
CI:90.4-92.7%
50.7% ± 12.5
CI:48.2-53.1%
50.7% ± 13.3
CI:48.1-53.3%
50.7% ± 14.1
CI:47.9-53.4%
MCI vs. control 84.2% ± 3.7
CI:83.4-84.9%
81.1% ± 5.6
CI:80.0-82.2%
87.7% ± 3.7
CI:87.0-88.5%
51.3% ± 11.4
CI:49.0-53.5%
52.0% ± 12.2
CI:50.0-54.4%
50.4% ± 13.5
CI:47.8-53.1%
PSY vs. control 97.1% ± 1.6
CI:96.8-97.4%
95.3% ± 1.7
CI:95.0-95.6%
99.0% ± 2.4
CI:98.5-99.4%
48.7% ± 10.6
CI:46.7-50.8%
48.5% ± 12.4
CI:46.0-50.9%
49.0% ± 12.1
CI:46.6-50.8%
Other ND vs. control 82.8% ± 5.0
CI:81.8-83.7%
84.0% ± 5.8
CI:83.0-85.2%
81.4% ± 6.7
CI:80.1-82.7%
50.3% ± 10.3
CI:48.3-52.3%
50.7% ± 11.7
CI:48.4-53.0%
50.0% ± 12.0
CI:47.6-52.3%
NEURO vs. control 86.1% ± 5.7
CI:85.0-87.2%
88.7% ± 6.8
CI:87.3-90.0%
83.6% ± 6.6
CI:82.3-84.9%
49.9% ± 10.8
CI:47.8-52.1%
50.1% ± 11.5
CI:47.9-52.3%
49.8% ± 13.3
CI:47.2-52.3%
AD vs. MCI 75.6% ± 7.8
CI:74.1-77.2%
76.7% ± 8.3
CI:75.1-78.4%
74.6% ± 9.7
CI:72.7-76.5%
50.6% ± 9.4
CI:48.7-52.4%
51.2% ± 10.4
CI:49.1-53.2%
49.9% ± 11.7
CI:47.7-52.2%
AD vs. PSY 77.8% ± 4.0
CI:77.0-78.5%
76.3% ± 4.8
CI:75.4-77.3%
79.2% ± 5.4
CI:78.1-80.2%
50.0% ± 8.0
CI:48.5-51.6%
49.1% ± 9.3
CI:47.3-50.9%
51.1% ± 10.3
CI:49.1-53.1
AD vs. other ND 73.8% ± 4.4
CI:72.9-74.7%
75.2% ± 4.7
CI:74.2-76.1%
72.4% ± 6.4
CI:71.2-73.7%
50.1% ± 7.3
CI:48.7-51.5%
49.2% ± 9.4
CI:47.4-51.1%
51.0% ± 8.5
CI:49.3-52.7%
The right part of the table contains the results for the permuted class labels. PSY = psychological disorders (DEP, BD, SCHIZ), other ND = other
neurodegenerative disorders (PD, MS, MCI), NEURO = PSY + other ND
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AD was SCHIZ, where we found six up- and six downre-
gulated miRNAs. We found a strong overall downregula-
tion for most of the selected 12 miRNAs for patients
with DEP and PD and a strong overall upregulation for
patients with MCI, CIS, and BD (Figure 3).
In addition, we also applied machine learning proce-
dures using SVM to estimate the accuracy, sensitivity,
and specificity of the 12-miRNA signature regarding the
other neurological diseases in comparison to the control
group and to AD. The results of these classifications are
also listed in Table 2. Interestingly, while the 12 miRNAs
were chosen for their potential to separate AD and con-
trols, this signature also separates the group of the psy-
chological disorders (DEP, BD, SCHIZ) from controls
with an accuracy of 97.1%, a specificity of 95.3%, and a
sensitivity of 99.0% whereas other neurodegenerative dis-
eases (PD, multiple sclerosis, mild cognitive impairment)
were separated from controls with a worse accuracy of
82.8%, a specificity of 84.0%, and a sensitivity of 81.4%.
The average accuracy for the other classifications against
controls (that is, MCI versus control and neurodegenera-
tive and psychological disorders versus control) reached
values of 84.2% and 86.1%, respectively. Furthermore,
we tested how well the 12-miRNA signature separates
AD from MCI, AD from psychological disorders, and
AD from other neurodegenerative diseases, respectively.
The average accuracy for these comparisons was between
73.8% and 77.8%. Since the 12-miRNA signature has
been tailored to differentiate between AD and controls,
other miRNAs may likely contribute to a signature that
permits also a better differentiation between the other
tested diseases and AD.
Prediction of miRNA targets and over-representation
analysis
Target gene prediction of the 10 known miRNAs from the
12-miRNA signature revealed 2,354 genes that may be
regulated by those miRNAs. These target genes were used
to perform an over-representation analysis and identified
73 computed Gene Ontology (GO) categories with P
values <0.05 and FDR adjustment. Interestingly, we found
a significant enrichment of miRNA targets in the GO cate-
gories nervous system development, neuron projection,
neuron projection development, and neuron projection
morphogenesis. These GO categories are listed in Table 3
together with the predicted miRNA target genes involved
in these categories. Furthermore, target genes that have
already been related to AD or other neurological diseases
are also listed in the table in separate columns.
Target gene prediction for the two unknown target
genes brain-miR-112 and brain-miR-161 revealed 234
target genes for brain-miR-112, but only six target genes
Figure 3 Results of the RT-qPCR analysis of the 12 miRNAs in each of the analyzed diseases. ΔΔCT values of the patients groups as
compared to controls are shown on the y-axis. A lower expression in the patients than in controls is indicated by the bars <0 and higher
expression in the patients as compared to controls is indicated by the bars >0. (C = healthy control, AD = Alzheimer disease, MCI = mild
cognitive impairment, PD = Parkinson disease, DEP = major depression, CIS = multiple sclerosis (clinically isolated syndrome), SCH =
schizophrenia, BD = bipolar disorder).
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Table 3 Results of the over-representation analysis of the predicted target genes of the 10 known miRNAs.
Subcategory Subcategory
alternative
name
Expected Observed Pvalue
(FDR)
Target genes AD BD DEP PD SCHIZ Multiple
sclerosis
Nervous
system
development
GO:0007399 159,555 215 0,000921692 ARSB ATM GJA1 JAG1 LEP NDP PTEN PAFAH1B1
TWIST1 DRD1 IGF1R GDF6 SMPD1 KCNMA1
NTRK2 CTNS NF1 INSC SLC6A3 FBXO45 IGF1
ADM APC DLG4 GRIN2A PAX7 PPT1 GPSM1
FEZF1 TSC1 DISC1 GLRB BMPR1B CDK6 CX3CR1
CELSR2 ID4 ERBB3 FGF2 AFF2 GLRA2 GSK3B
HOXB3 LAMC1 LRP6 LSAMP NGF NPAS2 OPHN1
P2RY1 PEX13 POU3F1 PTPRZ1 SALL1 SMARCC1
STRN T TFAP2A TGFB2 TIAM1 NR2C2 YWHAH
ZIC1 ULK1 ENC1 IRS2 ADAM23 KALRN SEMA5A
EDNRB DMD AQP4 GMFB SDHA SLC1A2 GDA
VCAN DVL1 EPHA4 EPHA7 KIF5C LRP2 POU4F2
RPS6KA3 SPOCK1 TGFBR1 AXIN2 DCLK1 MED1
ONECUT2 SIM1 CNTN2 ATF1 DLX6 ERBB4
SMAD4 SIX3 NHLH1 POU3F2 REST ABI2 PURA
SMAD1 NAB1 SIX1 PPARD PRKCQ CHERP
MAB21L2 TBR1 CHL1 FRS2 FKTN BTG2 SHOX2
SLC5A3 ZNF24 WWP1 STMN2 RAPGEF5 PIP5K1C
ATXN10 RACGAP1 GREM1 NRG1 CNTNAP2
RPS6KA6 CYFIP1 ULK2 NLGN1 RUFY3 ARHGAP26
NFASC CLASP2 NIPBL SUFU PDGFC HPCAL4
RAPGEFL1 SHC3 FZD3 SIX4 BAIAP2 CSGALNACT1
PCDHB10 NMUR2 VANGL2 SEMA6A CNTN3
LRRC4C RET GNAO1 SCN2A FGF12 XRCC5 NTN4
BCR ADAM22 ACSL4 FGFR1 HTR5A NOTCH2
TTLL7 PGAP1 JHDM1D ATXN3 ZEB1 NDEL1
MAP2 B3GNT5 CHD6 SLITRK6 ELAVL3 HOOK3
ATOH8 WNT3A ZIC5 FGF1 SOX6 PDE5A SNAP25
GRIN3A CREB1 NRXN1 NRXN3 TPM3 FYN
SEMA6D HOXA1 BDNF ALDH5A1 UNC5B DMBX1
IL6ST UHMK1 DCX CUX1 ATL1 GLDN RNF6
FAM5C CCNG1 NRP2 GAS7 ACSL3 RCAN1 SYNJ1
PCDH9 MOG RTN1 QKI LIG4 MBNL1 CCDC64
WNK1
DRD1
IGF1R
GSK3B
FGF1
FYN
BDNF
DRD1
DISC1
GSK3B BCR
HTR5A
BDNF
SYNJ1
BCR
SNAP25
CREB1
BDNF
BDNF LEP DRD1 SLC6A3
GRIN2A DISC1 YWHAH
SLC1A2 CHL1 NRG1
FZD3 HTR5A SNAP25
BDNF SYNJ1
JAG1
Neuron
projection
GO:0043005 49,9516 79 0,00411039 ADRB2 CA2 PAFAH1B1 ATP1A2 DRD1 GABRA6
GAD1 GRM3 IGF1R KCNJ2 NPY1R PGR AR
KCNMA1 NF1 TACR1 MYO5B ACTN2 GRM1 APC
GRIN2A ATXN1L MYO5A PPT1 OPRM1 TSC1
HTR2A CALCR OPHN1 STRN TGFB2 ULK1 PRSS12
KALRN BNIP3 SLC1A2 DVL1 EPHA7 KIF5C NCAM2
KIF5A CNTN2 ABI2 PURA CAPRIN1 IGF2BP1
SCN1A STMN2 SNCA STAT1 EPB41L3 ATXN10
CNTNAP2 RUFY3 NFASC ERC2 KIAA1598 SEMA6A
SCN2A GAN TTLL7 CPEB1 NDEL1 MAP2 PSD2
CALD1 SNAP25 GRIN3A TPM3 AQP11 UHMK1
EXOC8 DICER1 ATL1 ANKS1B RNF6 CCNG1
CACNA1C NRP2
DRD1
IGF1R
HTR2A
SNCA
DRD1
HTR2A
HTR2A SNCA DRD1 GAD1 GRM3
GRIN2A HTR2A SLC1A2
SNAP25
ADRB2
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Table 3 Results of the over-representation analysis of the predicted target genes of the 10 known miRNAs. (Continued)
Neuron
projection
development
GO:0031175 43,1466 67 0,0162232 GJA1 PTEN PAFAH1B1 IGF1R ADM APC FEZF1
DISC1 BMPR1B CELSR2 ERBB3 LAMC1 NGF
OPHN1 PTPRZ1 STRN TIAM1 YWHAH ULK1
KALRN DMD VCAN DVL1 EPHA4 EPHA7 KIF5C
POU4F2 DCLK1 CNTN2 ATF1 POU3F2 ABI2
SMAD1 TBR1 STMN2 PIP5K1C ATXN10 CYFIP1
ULK2 RUFY3 NFASC FZD3 BAIAP2 SEMA6A
LRRC4C GNAO1 ACSL4 FGFR1 NDEL1 MAP2
SLITRK6 WNT3A SNAP25 GRIN3A CREB1 NRXN1
NRXN3 HOXA1 BDNF UNC5B UHMK1 DCX ATL1
RNF6 NRP2 GAS7 CCDC64
IGF1R
BDNF
DISC1
BDNF
SNAP25
CREB1
BDNF
BDNF DISC1 YWHAH FZD3
SNAP25 BDNF
–
Neuron
projection
morphogenesis
GO:0048812 33,5906 52 0,0462928 GJA1 PAFAH1B1 IGF1R ADM APC FEZF1 BMPR1B
CELSR2 ERBB3 NGF OPHN1 PTPRZ1 TIAM1
YWHAH ULK1 KALRN DMD VCAN DVL1 EPHA4
EPHA7 KIF5C POU4F2 DCLK1 CNTN2 POU3F2
SMAD1 TBR1 PIP5K1C CYFIP1 ULK2 RUFY3
NFASC FZD3 BAIAP2 SEMA6A LRRC4C NDEL1
SLITRK6 WNT3A SNAP25 CREB1 NRXN1 NRXN3
HOXA1 BDNF UNC5B DCX ATL1 RNF6 NRP2
GAS7
BDNF
IGF1R
BDNF SNAP25
CREB1
BDNF
BDNF FZD3 SNAP25 BDNF
YWHAH
–
This table lists interesting Gene Ontology (GO) subcategories and over-represented target genes with Pvalues <0.05 and FDR adjustment related to nervous system development. Target genes associated with AD and
other neurological diseases are listed separately.
AD: Alzheimer disease; BP: bipolar disorder; DEP: major depression; PD, Parkinson’s disease; SCHIZ: schizophrenia
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for brain-miR-161. Over-representation analysis was
done for both brain-miRNAs separately. Here, we identi-
fied 126 GO categories with P value <0.05 for brain-miR-
112, with significant enrichment of miRNA targets in GO
categories associated with nervous system and neuron
function (see Table 4). For brain-miR-161 no significant
GO categories were found.
Discussion
At present, there is no single molecular test that is suitable
to reliably diagnose AD with adequate specificity and sen-
sitivity. Tests for the analysis of CSF proteins like Aß42 or
tau have high specificity and sensitivity, but are only indi-
cated as confirmation of AD diagnosis based on clinical
symptoms or as differential diagnosis to differentiate
between AD and other forms of diseases that can cause
symptoms like dementia. The analysis of SNPs in certain
genes (for example, ApoE) yields too low diagnostic accu-
racy and is therefore not recommended as diagnostic test
for AD. Furthermore, Ray et al. yielded promising results
by the identification of 18 proteins in blood plasma that
could differentiate AD patients from controls with 90%
accuracy [25].
Here, we investigate whether blood-borne miRNA
expression signatures might contribute to AD diagnosis.
Until now, many efforts have been made to understand
the role of miRNAs in neurodegenerative disorders, as
summarized by Eacker et al. [26]. However, there are only
two publications dealing with the miRNA expression in
peripheral blood mononuclear cells (PBMC) of AD
patients. The study by Villa et al. analyzed the expression
of heterogeneous nuclear ribonucleoprotein (hnRNP)-A1,
that is involved in the maturation of APP mRNA, and
showed that the decreased expression of hsa-miR-590-3p
is negatively correlated with the increased hnRNP-A1
mRNA levels [27]. The study by Schipper et al. [28] inves-
tigated the expression of 462 different miRNAs in PBMCs
of 16 AD patients and 16 healthy controls to identify miR-
NAs that are responsible for the regulation of transcrip-
tion of mRNA species that were previously reported to be
downregulated in PBMCs of AD patients [29]. Only a
modest relative increase of miRNA expression in AD
PBMC in the range of 1.1- to 1.4-fold was found for nine
miRNAs, namely hsa-miR-34a, hsa-miR-579, hsa-miR-
181b, hsa-miR-520h, hsa-miR-155, hsa-miR-517*, hsa-let-
7f, hsa-miR-200a, and hsa-miR-371. These data link the
development of AD pathology to systemic dysfunction in
the cellular stress/antioxidant response and genomic
maintenance [28].
Using high throughput sequencing, we identified 140
unique miRNAs from 180 precursors that were differen-
tially expressed between whole blood obtained from AD
patients and healthy controls. It is incumbent upon the
investigator, who proposes a set of miRNAs as done here
to examine whether there is any known connection of
these miRNAs and their target genes to neurodegenera-
tion. Below we discuss this aspect in respect to our find-
ings of dys-regulated miRNAs in blood of AD patients
compared to healthy controls.
According to our TAM analysis out of the downregu-
lated miRNAs, six were associated with the disease cate-
gory Alzheimer disease including hsa-miR-21, hsa-miR-17,
hsa-miR-29a, hsa-miR-29b, hsa-miR-106b, and hsa-miR-
107. In a mouse model, Wang et al. investigated the invol-
vement of hsa-miR-106b in the TGF-b signaling pathway
that plays a key role in the pathogenesis of AD and found
an inverse correlation between the expression of hsa-miR-
106b and TGF-b type II receptor (TbR II) protein level
[30]. In addition, Hebert et al. showed that hsa-miR-106b
affects the expression of Amyloid precursor protein (APP)
in vitro. Furthermore, they found a statistically significant
decrease in hsa-miR-106b expression in sporadic AD
patients, but the correlation between miR-106b and APP
expression in AD brain was not significant [31]. The same
group showed an inverse correlation between increased
BACE1 levels and decreased miR-29a/b-1 expression [15].
Shioya et al. also observed a decreased expression of hsa-
miR-29a in brain tissue of AD patients [32]. They also
identified neuron navigator 3 (NAV3), a regulator of axon
guidance, as a target of hsa-miR-29a and found elevated
NAV3 mRNA levels in AD brains [32]. Hsa-miR-17 was
shown to regulate APP expression in vitro and under phy-
siological conditions in cells [31,33]. MiR-21 was shown to
be downregulated in time-course assays of mature murine
primary hippocampal cell cultures after neuronal Ab treat-
ments [34].
We further performed over-representation analysis with
the 2,354 predicted targets of the 10 known miRNAs of
our 12-miRNA signature. Here, several GO categories,
with significant enrichment of miRNA targets in the GO
categories linked to the nervous system, were found. Most
interestingly, some of these target genes have already been
related to AD or other of the investigated neurological dis-
eases. One of the most prominent examples is DRD1 that
encodes the Dopamine receptor D1, which is the most
abundant dopamine receptor in the central nervous sys-
tem. DRD1 is associated with AD, BD, and SCHIZ.
Another example, DISC1 (disrupted in SCHIZ), associated
with BD and SCHIZ, encodes a protein involved in neurite
outgrowth and cortical development. BDNF (brain-derived
neurotrophic factor) important for survival of striatal neu-
rons in the brain is known to be downregulated in AD
patients and also associated with BD, DEP, PD, and
SCHIZ. IGF1R is the only target gene that was exclusively
found to be associated with AD. The protein encoded by
this gene is increased in temporal cortex surrounding and
within Aß-containing plaques, but a significantly lower
number of neurons of AD patients express IGF1R [35].
Leidinger et al. Genome Biology 2013, 14:R78
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Table 4 Results of the over-representation analysis of the predicted target genes of brain-miR-112.
Subcategory Subcategory
alternative
name
Expected Observed Pvalue
(FDR)
Target genes AD BD DEP PD SCHIZ Multiple
sclerosis
Neurogenesis GO:0022008 119.612 31 0.000284421 ONECUT2 ANK3 CACNB3 CDK6 CELSR3 FGFR2 MEF2A NFIB PICALM PLAG1
PLXNA1 PSD4 PTPRR RAB11A RPS6KA4 SIX4 COL4A4 DFNB31 DISC1 SRF
STX3 ADCY1 CDKN1C CNP ENAH HOXC10 LIF LRP6 ROCK1 RPS6KA3
TFAP2A
– DISC1 – – DISC1 –
Neuron
differentiation
GO:0030182 103.937 27 0.000801251 ONECUT2 ANK3 CACNB3 CELSR3 FGFR2 MEF2A NFIB PICALM PLXNA1
PSD4 PTPRR RAB11A RPS6KA4 COL4A4 DFNB31 SRF STX3 ADCY1 CDKN1C
CNP ENAH HOXC10 LIF LRP6 ROCK1 RPS6KA3 TFAP2A
– – – – – –
Neuron
development
GO:0048666 845.125 23 0.00159317 ONECUT2 ANK3 CACNB3 CELSR3 FGFR2 MEF2A NFIB PICALM PLXNA1
RAB11A RPS6KA4 COL4A4 DFNB31 SRF STX3 ADCY1 CDKN1C CNP ENAH
LIF ROCK1 RPS6KA3 TFAP2A
– – – – – –
Nervous system
development
GO:0007399 184.019 37 0.00268227 ONECUT2 ANK3 CACNB3 CDK6 CELSR3 FGFR2 MEF2A NFIB PICALM PLAG1
PLXNA1 PSD4 PTPRR RAB11A RPS6KA4 SEMA5B SIX4 COL4A4 DFNB31
DISC1 FGF1 SRF STX3 SULF1 ADCY1 ARHGEF15 CDKN1C CNP ENAH
HOXC10 LIF LPHN1 LRP6 MEN1 ROCK1 RPS6KA3 TFAP2A
FGF1 DISC1 – – DISC1 –
Neuron projection
development
GO:0031175 736.077 19 0.00946322 ANK3 CACNB3 CELSR3 FGFR2 MEF2A NFIB PICALM PLXNA1 RAB11A
RPS6KA4 COL4A4 SRF STX3 ADCY1 CNP ENAH LIF ROCK1 RPS6KA3
– – – – – –
Neuron projection GO:0043005 633.844 16 0.0262424 ALOX5 ANK3 MYLK2 NFIB SLC38A7 DFNB31 DISC1 FRMPD4 GRIA4 SLC6A1
STX3 AAK1 ALDOC ARHGEF15 BACE1 LPHN1
BACE1 DISC1 – – DISC1
GRIA4
–
Neurotransmitter:
sodium symporter
activity
GO:0005328 0.215825 3 0.0330004 SLC6A20 SLC6A1 SLC6A6 – – – – – –
Neuron projection
morphogenesis
GO:0048812 624.756 15 0.0391162 ANK3 CACNB3 CELSR3 FGFR2 MEF2A NFIB PICALM PLXNA1 RPS6KA4
COL4A4 ADCY1 CNP ENAH ROCK1 RPS6KA3
– – – – – –
Neurotransmitter
transporter activity
GO:0005326 0.272621 3 0.0412241 SLC6A20 SLC6A1 SLC6A6 – – – – – –
Neuroblast division GO:0055057 0.0795144 2 0.0412241 FGFR2 LRP6 – – – – – –
Forebrain neuroblast
division
GO:0021873 0.0795144 2 0.0412241 FGFR2 LRP6 – – – – – –
Generation of
neurons
GO:0048699 112.797 31 0.000188727 ONECUT2 ANK3 CACNB3 CDK6 CELSR3 FGFR2 MEF2A NFIB PICALM PLAG1
PLXNA1 PSD4 PTPRR RAB11A RPS6KA4 SIX4 COL4A4 DFNB31 DISC1 SRF
STX3 ADCY1 CDKN1C CNP ENAH HOXC10 LIF LRP6 ROCK1 RPS6KA3
TFAP2A
– DISC1 – – DISC1 –
Cell morphogenesis
involved in neuron
differentiation
GO:0048667 616.805 15 0.0366659 ANK3 CACNB3 CELSR3 FGFR2 MEF2A NFIB PICALM PLXNA1 RPS6KA4
COL4A4 ADCY1 CNP ENAH ROCK1 RPS6KA3
– – – – – –
This table lists interesting Gene Ontology (GO) subcategories with Pvalues <0.05 and FDR adjustment related to nervous system development.
AD: Alzheimer disease; BP: bipolar disorder; DEP: major depression; PD, Parkinson’s disease; SCHIZ: schizophrenia
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This suggests that IGF1R signaling normally controlling
vital growth, survival, and metabolic functions in the brain
is disturbed in AD brains. The two unknown miRNAs
revealed 234 target genes for brain-miR-112, but only six
target genes for brain-miR-161. In the over-representation
analysis for brain-miR-112 we also identified GO cate-
gories linked to the nervous system, including targets like
DISC1 as discussed above. For brain-miR-161 we found
no significant GO categories. However, a literature review
of the six target genes of brain-miR-161 revealed some
interesting findings. GRID1 (glutamate receptor, ionotro-
pic, delta 1), predicted to be a target gene of brain-miR-
161, encodes a gene product that is a subunit of glutamate
receptor channels which mediate most of the fast excita-
tory synaptic transmission in the central nervous system
and play key roles in synaptic plasticity. Interestingly,
GRID1 has previously been associated with SCHIZ and
BD [36-38]. Another predicted target gene CCDN2
(Cyclin D2) plays a role in corticogenesis [39].
However, we have to point out that our analysis is
based on whole blood. Previous findings on cancer sug-
gest that the miRNA expression pattern between blood
cells and cancer tissue do not necessarily show the same
expression pattern but some overlaps can be found
[40-42]. Unfortunately, tissue and blood samples of the
same patients were not available for the present study.
Nevertheless, we performed database analysis and
extracted all miRNAs deregulated in AD and the corre-
sponding literature out of the Human MiRNA& Disease
Database [43]. In total, we found 18 different publica-
tions, with 15 publications on AD brain tissue and/or cell
culture models. Out of those studies, 29 different miR-
NAs deregulated in AD are listed in the HMDD. Com-
paring these miRNAs with our data revealed eight of the
29 miRNAs that were significantly dys-regulated in blood
cells in our study. There is, however, no evidence
whether these overlaps were found by chance or not. Any
link between deregulated miRNAs in blood of patients
with neurological diseases and the disease itself has to be
considered with caution.
Since a large set of miRNAs often contains a significant
amount of redundant miRNAs with largely identical infor-
mation content the differentiation between AD samples
and healthy controls using a reduced set of miRNAs may
likely yield comparably accurate results. Therefore, a panel
of 12 miRNAs with limited cross-correlation, including
most strongly dys-regulated miRNAs that show a potential
to separate AD from controls, was selected. Some of these
12 miRNAs have already been related to AD. For example,
Wang et al. showed in a computational analysis that the
3’-untranslated region (UTR) of beta-site amyloid precur-
sor protein-cleaving enzyme 1 (BACE1) mRNA is targeted
by hsa-miR-107 and that BACE1 mRNA levels tended to
increase as miR-107 levels decreased in the progression
for AD. An increased BACE1 expression is an important
risk factor for sporadic AD [15]. Nelson et al. also showed
a negative correlation between the expression of hsa-miR-
107 and BACE1 [44]. Interestingly, hsa-miR-107 that was
also part of our 12-miRNA signature investigated in the
presented study was also downregulated in blood of AD
patients compared to healthy controls. Augustin et al. [45]
recently investigated miRNAs that are predicted to target
another AD-related gene, namely ADAM10, which con-
trols the proteolytic processing of APP and the formation
of the amyloid plaques. Database analyses prompted them
to further investigate two miRNAs that were also included
in our 12-miRNA signature, namely hsa-miR-107 and hsa-
miR-103. They found that predicted target genes of hsa-
miR-107 and hsa-miR-103 showed significant overlap with
the AlzGene database. In a reporter assay ADAM10
expression was reduced by both miRNAs. These two miR-
NAs were also investigated in relation to the expression of
cofilin protein in a transgenic mouse model [46]. Cofilin
binds to actin resulting in the formation of Hirano bodies,
which may play an essential role in AD pathogenesis. In
APP transgenic mouse brains hsa-miR-107 and hsa-miR-
103 levels were decreased while cofilin levels were
increased and in a luciferase assay it was demonstrated
that hsa-miR-107 and hsa-miR-103 were able to reduce
the expression of cofilin. In our RT-qPCR approach both
miRNAs hsa-miR-107 and hsa-miR-103 showed the same
expression pattern, that is, both were downregulated in
blood of AD, PD, DEP, and SCHIZ patients and upregu-
lated in mild cognitive impairment, multiple sclerosis, and
BD patients. All other miRNAs of our 12-miRNA signa-
ture have not been identified or investigated so far in rela-
tionship to AD.
While we showed the 12-miRNA signature’s potential to
separate AD patients from controls with an accuracy of
93.3%, we also tested its applicability as differential diag-
nostic biomarker to separate AD from other neurological
diseases. As we expected, the accuracy decreased when
trying to use this signature for separating other neurode-
generative diseases from controls or separating AD from
other neurological disorders. Remarkably, the classification
of psychiatric disorders versus controls yielded an even
better accuracy than for AD versus controls. These find-
ings suggest a relevance of the considered 12 miRNAs also
for psychological disorders. The association of the 12-
miRNA signature with neurological diseases in general is
further underlined by the results of our over-representa-
tion analysis using GeneTrail. Here, we found four signifi-
cant GO categories related to nervous system and neurons
with an over-representation of target genes of the 10
known miRNAs from our 12-miRNA signature. In addi-
tion, out of the 10 known miRNAs nine miRNAs are
already included in the HMDD and five of those miRNAs
that were previously associated with neurological diseases
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including AD, PD, and SCHIZ. As mentioned above, Yao
et al. [46] showed that reduced levels of hsa-miR-103 or
hsa-miR-107 are associated with elevated cofilin protein
levels and formation of rod-like structures in a transgenic
mouse model of AD. Both miRNAs were also downregu-
lated in our study. Martins et al. [47] showed that hsa-
miR-151a-3p and hsa-miR-26a-5p are differentially
expressed in PBMCs (peripheral blood mononuclear cells)
of PD patients and controls. In prefrontal cortex tissue of
individuals with SCHIZ hsa-miR-26b was downregulated
[48]. Target analysis of the miRNA that was not included
in HMDD, hsa-miR-5010-3p, revealed target genes
involved in nervous system processes. For example, pre-
dicted targets of hsa-miR-5010-3p include the NFASC
(neurofascin), that functions in neurite outgrowth, and
organization of nodes of Ranvier on axons, NPY (Neuro-
peptide Y), that is one of the most abundant neuropep-
tides in the mammalian central nervous system [49],
NLGN1 (neuroligin 1), that may be involved in the forma-
tion and remodeling of central nervous system synapses,
NRXN3 (neurexin3), that functions in the nervous system
as receptors and cell adhesion molecule, and NCAN (neu-
rocan), that seems to be a genetic risk factor for BD.
Finally, one has to take into account that AD is a com-
plex progressive neurodegenerative disease causing cogni-
tive, behavioral, and functional problems that are also
found in other neurological diseases. Furthermore, demen-
tia is not only caused by AD but can result from other
neurological disorders. Dementia patients often suffer
from other additional mental and behavioral problems like
depression, anxiety, psychosis, agitation, and aggression
further complicating correct classification. As AD shares
common neuropsychiatric symptoms with other neurolo-
gical diseases there might be an overlap with the asso-
ciated medication.
Most importantly one needs to point out that as the
patients included in our study are not treatment-naïve,
we cannot exclude the influence of administered drugs on
the miRNA signature. As an example, Bocchio-Chiavetto
et al. showed that chronic anti-depressant treatment has
effects on the blood miRNA profile [50]. Furthermore, we
have to point out that we do not have a birth cohort.
Nevertheless, the age distribution between the AD samples
and the control samples used for NGS is not significantly
different (P value 0.1147). The age distribution of AD
patients, MCI patients, PD patients, and controls is quite
similar. Patients suffering from multiple sclerosis, DEP,
BD, or SCHIZ are about 20 to 30 years younger. The dif-
ferences in the age distribution are due to the differences
between the onsets of the diseases. In previous studies [51]
we already investigated the influence of age and gender on
the miRNA expression profile of whole blood. We did not
find any statistically significant deregulated miRNAs
between men and women. The miRNA with the lowest
P value was hsa-miR-423 (P value 0.78). To test for the
influence of age we compared the profiles obtained from
old versus young patients by splitting the total group in
half based on the age. Here, the miRNA with the lowest P
value was hsa-miR-890 (P value 0.87). Again, we did not
find any deregulated miRNAs. In summary, we found no
evidence that age and gender have a substantial influence
on the miRNA profiles. Both miRNAs mentioned above
were not significant in the present study on AD.
Conclusion
Here we identified 140 unique differentially expressed
miRNAs between AD patients and healthy controls. Using
a signature of 12 miRNAs differentially expressed between
AD patients and healthy controls we were not only able to
distinguish with high diagnostic accuracies between AD
patients and healthy controls, but also between AD
patients and patients suffering from other neurological dis-
orders including mild cognitive impairment as a potential
preliminary stage of AD, and other neurodegenerative dis-
eases like PD and multiple sclerosis as well as mental dis-
eases like SCHIZ, DEP, and BD. However, additional work
will be needed to elucidate the applicability of this 12-
miRNA signature as a potential diagnostic test for AD and
the above-mentioned effects of the drug treatments com-
monly used in the treatment of the disease. Hopefully,
tests of this non-invasive and relatively cheap kind will be
applicable to prodromal AD cases and to MCI patients
with the aim to recognize early AD to initiate treatment.
Materials and methods
Patient details
We analyzed the expression of miRNAs in peripheral
blood of a total of 215 patients and healthy controls,
either by NGS or by RT-qPCR or by both methods (see
Table 1). In detail, we obtained 2.5 mL blood collected in
PAXgene Blood RNA tubes (PreAnalytiX) from patients
with AD (n = 106), patients with mild cognitive impair-
ment (MCI) (n = 18), patients with multiple sclerosis
(clinically isolated syndrome, CIS) (n = 16), patients with
PD (n = 9), patients with DEP (n = 15), patients with BD
(n = 15), patients with SCHIZ (n = 14), and from healthy
controls (C) (n = 22). Samples from patients with AD
stem from the Biorepository and Tissue Bank Preci-
sionMed (San Diego, CA, USA) (n = 97) and the Univer-
sity Clinic of Erlangen (Germany) (n = 9), samples from
healthy controls and from patients with MCI, PD, DEP,
BD, and SCHIZ stem from PrecisionMed (San Diego,
CA, USA) and samples from patients with CIS stem from
Charité Berlin (Germany). Detailed patient characteristics
are listed in Additional file 4-Table S3. AD and MCI
patients were diagnosed by using state of the art criteria.
In detail, in order to be included in the ‘probable AD’
group, patients fulfilled the following criteria of the
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NINCDS-ADRDA (National Institute of Neurological
and Communicative Disorders and Stroke and the Alz-
heimer disease and Related Disorders Association) [52]:
MMSE >14 and <26, deficit in two or more areas of cog-
nition, progressive worsening of memory and other cog-
nitive functions, no disturbance of consciousness, onset
between the ages of 40 and 90 years, most often after 65
years, and absence of systemic disorders or other brain
diseases that could account for the progressive deteriora-
tion in cognition. Furthermore, MRI or CT reports that
were compatible with AD are available. The median
MMSE score for the AD patients was 18.9 (3.4).
Samples included in the MCI group fulfilled the follow-
ing criteria: MMSE >22 and <28, not demented, memory
complaint, preserved general cognitive function, intact
activities of daily living: (allowed problems with 2 or less
of the following: phone calls, meal preparation, handling
money, completing chores), abnormal memory function
documented by scoring below the education adjusted
cutoff on the Logical Memory II subscale (delayed para-
graph recall) from the Wechsler Memory Scale-Revised
(maximum score = 25) with (a) <8 for 16 years or more
of education, (b) <4 for 8-15 years of education, (c) <2
for 0-7 years of education. The median MMSE score for
the MCI patients was 25.3 (±1.4).
The study was approved by the institutional review
boards of Charité - Universitätsmedizin Berlin (EA1/182/
10) and the study was performed in accordance with the
Helsinki declaration. Written informed consent was
obtained from all patients participating in the study.
Samples and clinical data supplied by PrecisionMed are
handled in strictest compliance with all applicable rules
and regulations including the recommendations of the
Council of the Human Genome Organization (HUGO)
Ethical, Legal, and Social Issues Committee (HUGO-ELSI,
1998); with the United Nations Educational, Scientific, and
Cultural Organization’s (UNESCO) Universal Declaration
on the Human Genome and Human Rights (1997); and
with recommendations guiding physicians in biomedical
research involving human subjects adopted by the 18th
World Medical Assembly, Helsinki, Finland, 1964 and
later revisions.
RNA isolation
Total RNA including miRNA was isolated using the PAX-
gene Blood miRNA Kit (Qiagen) following the manufac-
turer’s recommendations. Isolated RNA was stored at -80°
C until use. RNA integrity was analyzed using Bioanalyzer
2100 (Agilent) and concentration and purity were mea-
sured using NanoDrop 2000 (Thermo Scientific).
Library preparation and next-generation sequencing
We first analyzed samples from AD patients (n = 48)
and healthy controls (n = 22) by NGS.
For the library preparation, 200 ng of total RNA was
used per sample, as determined with a RNA 6000 Nano
Chip on the Bioanalyzer 2100 (Agilent). Preparation was
performed following the protocol of the TruSeq Small
RNA Sample Prep Kit (Illumina). Concentration of the
ready prepped libraries was measured on the Bioanalyzer
using the DNA 1000 Chip. Libraries were then pooled in
batches of six samples in equal amounts and clustered
with a concentration of 9 pmol in one lane each of a single
read flowcell using the cBot (Illumina). Sequencing of 50
cycles was performed on a HiSeq 2000 (Illumina). Demul-
tiplexing of the raw sequencing data and generation of the
fastq files was done using CASAVA v.1.8.2.
NGS data analysis
The raw Illumina reads were first preprocessed by cutting
the 3’ adapter sequence using the program fastx_clipper
from the FASTX-Toolkit [53]. Reads shorter than 18 nts
after clipping were removed. The remaining reads are
reduced to unique reads and their frequency per sample to
make the mapping steps more time efficient. For the
remaining steps, we used the miRDeep2 pipeline [54].
These steps consist of mapping the reads against the gen-
ome (hg19), mapping the reads against miRNA precursor
sequences from miRBase release v18, summarizing the
counts for the samples, and the prediction of novel miR-
NAs. Since the miRDeep2 pipeline predicts in our case the
novel miRNAs per sample, we merged the miRNAs after-
wards as follows: first, we extract the novel miRNAs per
sample that have a signal-to-noise ratio >10. Subsequently,
we merge only those novel miRNAs that are located on
the same chromosome, and both their mature forms share
an overlap of at least 11 nucleotides. The remaining puta-
tive novel miRNAs were mapped with BLAST (v 2.2.24,
[55]) against known ncRNA and miRNA sequences from
diverse sources (miRBase v18 [56], snoRNA-LBME-db
[57], ncRNAs from Ensembl ‘Homo_sapiens.GRCh37.67.
ncrna.fa’[58], NONCODE v3.0[59]). We excluded
sequences that aligned with >90% of their length (allowing
1 mismatch) to any of the ncRNA sequences. All NGS
data are publicly available in GEO database (GSE46579
[60]).
Bioinformatics analysis
For the NGS analysis, we excluded miRNAs with <50
read counts summed up across all samples of each group
(AD or control), since these were considered lowly abun-
dant. We normalized the read counts using standard
quantile normalization. Next, we calculated for each
miRNA the area under the receiver operator characteris-
tic curve (AUC), the fold-change, and the significance
value (P value) using Wilcoxon-Mann-Whitney (WMW)
test. All significance values were adjusted for multiple
testing using the Benjamini-Hochberg approach [61,62].
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The bioinformatics analyses have been carried out using
the freely available tool R [63]. For classification pur-
poses, we used support vector machines (SVM) from the
R package e1071. If not stated otherwise, we computed
the group-wise classifications using linear kernels in
10-fold cross-validations with 100 repetitions. In addi-
tion, we computed the classification of permuted class
labels with the same parameters as control. If group sizes
were unbalanced, we randomly selected samples from the
bigger group to match the sample sizes in the smaller
group in each repetition.
Database analysis
MiRNA enrichment analysis was performed using the
TAM tool [23,24]. The miRNA targets of the known
miRNAs were predicted using miRDB [64-66]. Targets
for the unknown brain-miRs were predicted using Tar-
getScan [67,68]. TargetScan is able to predict targets of
miRBase miRNAs as well as targets of other sequences
by using the heptamer seed sequence (nucleotides 2-8)
of a potential miRNA. For brain-miR-161 we used the
heptamer UUCGAAA, for brain-mir-112 GCUCUGU.
With the predicted miRNA target genes we performed
an over-representation analysis using the gene set analy-
sis tool GeneTrail [69,70] with default settings. The
P values for the biological categories were adjusted by
False Discovery Rate (FDR) [71] and were considered
significant if <0.05. Furthermore, we searched for
miRNA-disease interactions using the Human MiRNA&
Disease Database (HMDD [43,72]).
Quantitative real time-PCR (RT-qPCR)
For validation purposes we analyzed the expression of
single miRNAs using quantitative real time-polymerase
chain reaction (RT-qPCR) in the same samples as used
for NGS, if sufficient amounts of RNA were available.
We used the miScript PCR System (Qiagen) for reverse
transcription and RT-qPCR. A total of 200 ng RNA was
converted into cDNA using the miScript Reverse Tran-
scription Kit according to the manufacturer’s protocol.
The RT-qPCR was performed with the miScript SYBR®
Green PCR Kit in a total volume of 20 μL per reaction
containing 1 μL cDNA according to the manufacturer’s
protocol. For each miScript Primer Assay we addition-
ally prepared a PCR negative-control with water instead
of cDNA (non-template control).
We further expanded the number of samples by further
samples from patients with AD, MCI, CIS, PD, DEP, BD,
and SCHIZ, resulting in a total of 202 samples analyzed by
RT-qPCR (see Table 1). In detail, we analyzed with RT-
qPCR a total of 94 samples from AD patients, 18 samples
from MCI patients, 16 samples from CIS patients, nine
samples from PD patients, 15 samples from DEP patients,
15 samples from BD patients, 14 samples from SCHIZ
patients, and 21 samples from healthy controls.
Out of the NGS results we selected 12 miRNAs
deregulated between patients with AD and healthy indi-
viduals. The set contained the following miRNAs: The
upregulated miRNAs brain-miR-112, brain-miR-161,
hsa-let-7d-3p, hsa-miR-5010-3p, hsa-miR-26a-5p, hsa-
miR-1285-5p, and hsa-miR-151a-3p as well as the down-
regulated miRNAs hsa-miR-103a-3p, hsa-miR-107, hsa-
miR-532-5p, hsa-miR-26b-5p, and hsa-let-7f-5p,
respectively.
While 10 of the 12 miRNAs have already been anno-
tated in the miRBase, two miRNAs, namely brain-miR-
112 and brain-miR-161, were newly identified and not
yet included in miRBase [21,22]. As endogenous control
we used the small nuclear RNA RNU48.
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Additional file 3: Table S2. Table listing all novel mature miRNAs.
Additional file 4: Table S3. Table listing patient characteristics and
indicates which samples are included in NGS analysis and/or in the RT-
qPCR.
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